London, UK; Brentwood, TN, US; 12 July 2007 - Protherics PLC (“Protherics” or the “Company”), the international biopharmaceutical company focused on critical care and cancer, today announces the maximum tolerated dose (“MTD”) of Prolarix(TM) has been determined in a phase 1 study being conducted under the auspices of Cancer Research UK. Prolarix(TM) is a novel targeted prodrug therapy being developed for the treatment of primary liver cancer (hepatocellular carcinoma) and other selected tumours.
